Diagnostic techniques and therapeutic challenges in patients with TP53 dysfunctional chronic lymphocytic leukemia

Giles Best, Philip Thompson, Constantine S. Tam

Research output: Contribution to journalReview articlepeer-review

5 Citations (Scopus)

Abstract

Aberrations of the TP53 pathway, whether by deletion or mutation, are increasingly recognized as one of the most important biological risk factors in chronic lymphocytic leukemia. Yet, there is little consensus on how to assess for TP53 defects in the clinic, and very few clinical studies to guide optimal management of such patients. In this review, we discuss the state-of-the-art in the assessment of the TP53 pathway, and review the evidence-base for therapeutic recommendations.

Original languageEnglish
Pages (from-to)2105-2115
Number of pages11
JournalLeukemia and Lymphoma
Volume53
Issue number11
DOIs
Publication statusPublished - Nov 2012
Externally publishedYes

Keywords

  • 17p deletion
  • Fludarabine
  • fluorescence in situ hybridization
  • rituximab

Fingerprint

Dive into the research topics of 'Diagnostic techniques and therapeutic challenges in patients with TP53 dysfunctional chronic lymphocytic leukemia'. Together they form a unique fingerprint.

Cite this